Pharmaceuticals And Biotechnology Option And Evaluation Agreements Report 2026 With Directory Of Deals Signed Since 2019 By Company A-Z, Therapeutic Area, Technology Type, And Industry Sector

(MENAFN- GlobeNewsWire - Nasdaq) Dublin, March 12, 2026 (GLOBE NEWSWIRE) -- The "Option and Evaluation Deals in Pharmaceuticals and Biotechnology 2019-2026" report has been added to ResearchAndMarkets's offering.
The Option and Evaluation Deals in Pharmaceuticals and Biotechnology 2019-2026 report provides a comprehensive analysis of option-based partnering agreements across the global life sciences industry. Designed for business development, licensing, and strategy professionals, the report delivers detailed insight into how companies structure option and evaluation partnerships, negotiate financial terms, and manage the transfer of development and commercialization rights.
Fully revised and updated, the report analyzes option and evaluation deals announced between 2019 and 2026, providing a detailed view of how pharmaceutical and biotechnology companies use option agreements to evaluate technologies, reduce development risk, and secure future licensing rights.
Each transaction includes financial information where available and links to detailed online deal records. Where agreements have been publicly filed, the report also provides access to the underlying contract documents submitted to regulators, enabling deeper insight into the detailed terms negotiated between partners.
By combining detailed deal data, financial benchmarking, and access to real contract agreements, the report provides valuable intelligence for evaluating potential partners, structuring option deals, and negotiating stronger agreements.
Key Benefits

• Save Significant Research Time: Access a comprehensive database of option and evaluation deals instead of searching multiple databases, press releases, and regulatory filings.
• Benchmark Option and Evaluation Deal Structures: Understand how pharmaceutical and biotechnology companies structure option-based partnerships, including evaluation rights, development options, and licensing pathways.
• Analyze Financial Terms with Confidence: Review disclosed payment structures and deal terms to benchmark the financial value and structure of comparable option transactions.
• Access Real Contract Documents: Where available, explore actual option and evaluation agreements filed with the SEC, providing deeper insight into the contractual provisions behind real-world deals.
• Identify the Most Active Option Dealmakers: Discover which companies are most active in option-based partnerships and analyze their strategic partnering activity.
• Track Industry Trends: Analyze option and evaluation dealmaking trends since 2019 across companies, therapeutic areas, and technology types.

What's Included in the Report

• Analysis of option and evaluation dealmaking trends since 2019
• Overview of option deal structures and evaluation partnership models
• Review of leading option and evaluation deals by headline value
• Profiles of the top 25 most active option and evaluation dealmakers
• Detailed analysis of deals organized by company, therapeutic area, technology type, and industry sector
• A comprehensive deal directory covering option and evaluation agreements announced since 2019
• Links to online deal records and contract documents where available

Due Diligence Insights from Real Agreements

• Option rights and evaluation periods
• Financial payment structures and option fees
• Development milestones and licensing triggers
• Intellectual property ownership and licensing rights
• Development and commercialization responsibilities
• Contract duration and termination provisions

Why This Report Matters
Option and evaluation agreements are widely used by pharmaceutical and biotechnology companies to assess promising technologies while limiting early-stage risk. These deals provide companies with the opportunity to evaluate assets before committing to full licensing or acquisition agreements.
By combining comprehensive deal data, financial benchmarking, and access to real contract documents, this report provides the intelligence needed to structure stronger option partnerships, evaluate emerging technologies, and negotiate more effectively.
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in option and evaluation dealmaking
2.1. Introduction
2.2. Definition of option and evaluation deal
2.3. Trends in option and evaluation deals since 2019
2.3.1. Option and evaluation dealmaking by year
2.3.2. Option and evaluation dealmaking by phase of development
2.3.3. Option and evaluation dealmaking by industry sector
2.3.4. Option and evaluation dealmaking by therapy area
2.3.5. Option and evaluation dealmaking by technology type
2.3.6. Option and evaluation dealmaking by most active company
2.4. Reasons for entering into option and evaluation partnering deals
2.5. The future of option and evaluation deals
Chapter 3 - Overview of option and evaluation deal structure
3.1. Introduction
3.2. Option and evaluation agreement structure
Chapter 4 - Leading option and evaluation deals
4.1. Introduction
4.2. Top option and evaluation deals by value
Chapter 5 - Top 25 most active option and evaluation dealmakers
5.1. Introduction
5.2. Top 25 most active option and evaluation dealmakers
Chapter 6 - option and evaluation deals including contracts directory
6.1. Introduction
6.2. Option and evaluation deals with contracts
Deal directory
Deal directory - option and evaluation dealmaking by companies A-Z
Deal directory - option and evaluation dealmaking by therapy area
Deal directory - option and evaluation dealmaking by technology type

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN12032026004107003653ID1110853526